{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:20:53Z","timestamp":1791231653680,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T00:00:00Z","timestamp":1531872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T00:00:00Z","timestamp":1531872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K16603"],"award-info":[{"award-number":["16K16603"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Renal tubulointerstitial injury, an inflammation-associated condition, is a major cause of chronic kidney disease (CKD). Levels of activated factor X (FXa), a blood coagulation factor, are increased in various inflammatory diseases. Therefore, we investigated the protective effects of an FXa inhibitor against renal tubulointerstitial injury using unilateral ureteral obstruction (UUO) mice (a renal tubulointerstitial fibrosis model) and the Food and Drug Administration Adverse Events Reporting System (FAERS) database. The renal expression levels of FX and the FXa receptors protease-activated receptor (PAR)-1 and PAR-2 were significantly higher in UUO mice than in sham-operated mice. UUO-induced tubulointerstitial fibrosis and extracellular matrix expression were suppressed in UUO mice treated with the FXa inhibitor edoxaban. Additionally, edoxaban attenuated UUO-induced macrophage infiltration and inflammatory molecule upregulation. In an analysis of the FAERS database, there were significantly fewer reports of tubulointerstitial nephritis for patients treated with FXa inhibitors than for patients not treated with inhibitors. These results suggest that FXa inhibitors exert protective effects against CKD by inhibiting tubulointerstitial fibrosis.<\/jats:p>","DOI":"10.1038\/s41598-018-29008-2","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T09:30:41Z","timestamp":1531387841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis"],"prefix":"10.1038","volume":"8","author":[{"given":"Yuya","family":"Horinouchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4318-7349","authenticated-orcid":false,"given":"Yasumasa","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijo","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8178-9028","authenticated-orcid":false,"given":"Yuki","family":"Izawa-Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7879-423X","authenticated-orcid":false,"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Takechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licht","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,18]]},"reference":[{"issue":"Suppl 1","key":"29008_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.2215\/CJN.05980809","volume":"4","author":"AJ Collins","year":"2009","unstructured":"Collins, A. J., Foley, R. N., Gilbertson, D. T. & Chen, S. C. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol 4(Suppl 1), S5\u201311 (2009).","journal-title":"Clin J Am Soc Nephrol"},{"key":"29008_CR2","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351, 1296\u20131305 (2004).","journal-title":"N Engl J Med"},{"key":"29008_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrneph.2014.114","volume":"10","author":"XM Meng","year":"2014","unstructured":"Meng, X. M., Nikolic-Paterson, D. J. & Lan, H. Y. Inflammatory processes in renal fibrosis. Nat Rev Nephrol 10, 493\u2013503 (2014).","journal-title":"Nat Rev Nephrol"},{"key":"29008_CR4","doi-asserted-by":"publisher","first-page":"e014294","DOI":"10.1136\/bmjopen-2016-014294","volume":"7","author":"MJ Huang","year":"2017","unstructured":"Huang, M. J. et al. Blood coagulation system in patients with chronic kidney disease: a prospective observational study. BMJ Open 7, e014294 (2017).","journal-title":"BMJ Open"},{"key":"29008_CR5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1055\/s-0038-1653865","volume":"73","author":"K Kario","year":"1995","unstructured":"Kario, K. et al. Marked increase of activated factor VII in uremic patients. Thromb Haemost 73, 763\u2013767 (1995).","journal-title":"Thromb Haemost"},{"key":"29008_CR6","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1097\/01.ASN.0000080315.37254.A1","volume":"14","author":"G Grandaliano","year":"2003","unstructured":"Grandaliano, G. et al. Protease-activated receptor-2 expression in IgA nephropathy: a potential role in the pathogenesis of interstitial fibrosis. J Am Soc Nephrol 14, 2072\u20132083 (2003).","journal-title":"J Am Soc Nephrol"},{"key":"29008_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1164\/rccm.200608-1097OC","volume":"175","author":"K Shinagawa","year":"2007","unstructured":"Shinagawa, K., Martin, J. A., Ploplis, V. A. & Castellino, F. J. Coagulation factor Xa modulates airway remodeling in a murine model of asthma. Am J Respir Crit Care Med 175, 136\u2013143 (2007).","journal-title":"Am J Respir Crit Care Med"},{"key":"29008_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.atherosclerosis.2015.03.023","volume":"242","author":"T Hara","year":"2015","unstructured":"Hara, T. et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis 242, 639\u2013646 (2015).","journal-title":"Atherosclerosis"},{"key":"29008_CR9","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1253\/circj.CJ-15-0285","volume":"79","author":"P Zuo","year":"2015","unstructured":"Zuo, P. et al. Effects of the factor Xa inhibitor, fondaparinux, on the stability of atherosclerotic lesions in apolipoprotein E-deficient mice. Circ J 79, 2499\u20132508 (2015).","journal-title":"Circ J"},{"key":"29008_CR10","doi-asserted-by":"publisher","first-page":"9453","DOI":"10.1158\/0008-5472.CAN-06-1803","volume":"66","author":"S Koizume","year":"2006","unstructured":"Koizume, S. et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 66, 9453\u20139460 (2006).","journal-title":"Cancer Res"},{"key":"29008_CR11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0031-6997(24)01493-5","volume":"53","author":"SR Macfarlane","year":"2001","unstructured":"Macfarlane, S. R., Seatter, M. J., Kanke, T., Hunter, G. D. & Plevin, R. Proteinase-activated receptors. Pharmacol Rev 53, 245\u2013282 (2001).","journal-title":"Pharmacol Rev"},{"key":"29008_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.molmed.2008.08.001","volume":"14","author":"K Borensztajn","year":"2008","unstructured":"Borensztajn, K., Peppelenbosch, M. P. & Spek, C. A. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med 14, 429\u2013440 (2008).","journal-title":"Trends Mol Med"},{"key":"29008_CR13","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1161\/ATVBAHA.116.307883","volume":"36","author":"Y Oe","year":"2016","unstructured":"Oe, Y. et al. Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy. Arterioscler Thromb Vasc Biol 36, 1525\u20131533 (2016).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"29008_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ejphar.2017.12.037","volume":"820","author":"T Hara","year":"2018","unstructured":"Hara, T. et al. Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury. Eur J Pharmacol 820, 222\u2013228 (2018).","journal-title":"Eur J Pharmacol"},{"key":"29008_CR15","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1248\/bpb.35.967","volume":"35","author":"K Kadoyama","year":"2012","unstructured":"Kadoyama, K., Sakaeda, T., Tamon, A. & Okuno, Y. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system. Biol Pharm Bull 35, 967\u2013970 (2012).","journal-title":"Biol Pharm Bull"},{"key":"29008_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.7150\/ijms.4549","volume":"9","author":"T Tamura","year":"2012","unstructured":"Tamura, T., Sakaeda, T., Kadoyama, K. & Okuno, Y. Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci 9, 441\u2013446 (2012).","journal-title":"Int J Med Sci"},{"key":"29008_CR17","doi-asserted-by":"publisher","first-page":"e42866","DOI":"10.1371\/journal.pone.0042866","volume":"7","author":"KB Hoffman","year":"2012","unstructured":"Hoffman, K. B., Kraus, C., Dimbil, M. & Golomb, B. A. A survey of the FDA\u2019s AERS database regarding muscle and tendon adverse events linked to the statin drug class. Plos One 7, e42866 (2012).","journal-title":"Plos One"},{"key":"29008_CR18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 10, 796\u2013803 (2013).","journal-title":"Int J Med Sci"},{"key":"29008_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/0886022X.2017.1279553","volume":"39","author":"T Uchida","year":"2017","unstructured":"Uchida, T. et al. Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis. Ren Fail 39, 340\u2013349 (2017).","journal-title":"Ren Fail"},{"key":"29008_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.yexcr.2004.10.021","volume":"304","author":"OP Blanc-Brude","year":"2005","unstructured":"Blanc-Brude, O. P. et al. Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation. Exp Cell Res 304, 16\u201327 (2005).","journal-title":"Exp Cell Res"},{"key":"29008_CR21","first-page":"365","volume":"39","author":"S Fiorucci","year":"2004","unstructured":"Fiorucci, S. et al. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology 39, 365\u2013375 (2004).","journal-title":"Role of proteinase receptors in stellate cell activation. Hepatology"},{"key":"29008_CR22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.bbrc.2016.12.108","volume":"483","author":"S Hayashi","year":"2017","unstructured":"Hayashi, S. et al. Protease-activated receptor 2 exacerbates adenine-induced renal tubulointerstitial injury in mice. Biochem Biophys Res Commun 483, 547\u2013552 (2017).","journal-title":"Biochem Biophys Res Commun"},{"key":"29008_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2353\/ajpath.2008.070347","volume":"172","author":"K Borensztajn","year":"2008","unstructured":"Borensztajn, K. et al. Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation. Am J Pathol 172, 309\u2013320 (2008).","journal-title":"Am J Pathol"},{"key":"29008_CR24","doi-asserted-by":"publisher","first-page":"e89355","DOI":"10.1371\/journal.pone.0089355","volume":"9","author":"Y Ikeda","year":"2014","unstructured":"Ikeda, Y. et al. Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction. Plos One 9, e89355 (2014).","journal-title":"Plos One"},{"key":"29008_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrm809","volume":"3","author":"JJ Tomasek","year":"2002","unstructured":"Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C. & Brown, R. A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3, 349\u2013363 (2002).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"29008_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/ki.1992.3","volume":"41","author":"RJ Alvarez","year":"1992","unstructured":"Alvarez, R. J. et al. Biosynthetic and proliferative characteristics of tubulointerstitial fibroblasts probed with paracrine cytokines. Kidney Int 41, 14\u201323 (1992).","journal-title":"Kidney Int"},{"key":"29008_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep26375","volume":"6","author":"T Nagashima","year":"2016","unstructured":"Nagashima, T., Shirakawa, H., Nakagawa, T. & Kaneko, S. Prevention of antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism. Sci Rep 6, 26375 (2016).","journal-title":"Sci Rep"},{"key":"29008_CR28","doi-asserted-by":"publisher","first-page":"e1603014","DOI":"10.1126\/sciadv.1603014","volume":"3","author":"N Hashikawa","year":"2017","unstructured":"Hashikawa, N. et al. HSP105 prevents depression-like behavior by increasing hippocampal brain-derived neurotrophic factor levels in mice. Sci Adv 3, e1603014 (2017).","journal-title":"Sci Adv"},{"key":"29008_CR29","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1248\/bpb.34.824","volume":"34","author":"A Sumi","year":"2011","unstructured":"Sumi, A. et al. Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db\/db mice. Biol Pharm Bull 34, 824\u2013830 (2011).","journal-title":"Biol Pharm Bull"},{"key":"29008_CR30","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.jacc.2017.09.1087","volume":"70","author":"X Yao","year":"2017","unstructured":"Yao, X. et al. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol 70, 2621\u20132632 (2017).","journal-title":"J Am Coll Cardiol"},{"key":"29008_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jtemb.2016.01.011","volume":"35","author":"Y Ikeda","year":"2016","unstructured":"Ikeda, Y. et al. Iron-induced skeletal muscle atrophy involves an Akt-forkhead box O3-E3 ubiquitin ligase-dependent pathway. J Trace Elem Med Biol 35, 66\u201376 (2016).","journal-title":"J Trace Elem Med Biol"},{"key":"29008_CR32","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1248\/bpb.b14-00191","volume":"38","author":"Y Suzuki","year":"2015","unstructured":"Suzuki, Y. et al. Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database. Biol Pharm Bull 38, 680\u2013686 (2015).","journal-title":"Biol Pharm Bull"},{"key":"29008_CR33","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1248\/bpb.b15-00243","volume":"38","author":"R Umetsu","year":"2015","unstructured":"Umetsu, R. et al. Association between Selective Serotonin Reuptake Inhibitor Therapy and Suicidality: Analysis of U.S. Food and Drug Administration Adverse Event Reporting System Data. Biol Pharm Bull 38, 1689\u20131699 (2015).","journal-title":"Biol Pharm Bull"},{"key":"29008_CR34","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1248\/bpb.b15-00253","volume":"38","author":"N Ueda","year":"2015","unstructured":"Ueda, N. et al. Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports. Biol Pharm Bull 38, 1638\u20131644 (2015).","journal-title":"Biol Pharm Bull"},{"key":"29008_CR35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5414\/CP202842","volume":"55","author":"M Fujimoto","year":"2017","unstructured":"Fujimoto, M., Kanou, M., Hosomi, K. & Takada, M. Angiotensin receptor blockers and the risk of cancer: data mining of a spontaneous reporting database and a claims database. Int J Clin Pharmacol Ther 55, 295\u2013303 (2017).","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29008-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29008-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29008-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T19:04:00Z","timestamp":1751742240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29008-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,18]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["29008"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-29008-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,18]]},"assertion":[{"value":"21 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Edoxaban was provided by Daiichi Sankyo Co., Ltd. (Tokyo, Japan). There are no further patents, products in development, or marketed products to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10858"}}